December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Panel moves to deconstruct itch
January 1st 2004Barcelona, Spain - Identifying the cause of itch is the key to treating it. New research is helping better characterize pruritus, leading to more effective therapies for this frustrating condition, according to physicians reporting at the 2003 meeting of the European Academy of Dermatology and Venereology (EADV).
Broaden your patients' treatment options
January 1st 2004Baltimore - PUVA and phototherapy are safe and effective for the treatment of more than two dozen conditions, but of the dermatologists who provide these treatments, as many as half use them solely for psoriasis, according to Warwick L. Morison M.D., professor of dermatology, Johns Hopkins Medical School, Baltimore.
Dermatologists are key players in smallpox war
January 1st 2004San Diego - With careful use, smallpox vaccination programs can be implemented on a large scale, and dermatologists will play a big role in its execution by assisting local health departments and preparing their professional colleagues, according to information presented by Colonel John D. Grabenstein, R.Ph., Ph.D., at the recent Infectious Diseases Society of America's annual meeting, held here.
FDA panel recommends label change
January 1st 2004Washington, D.C. - Responding to concerns over increased malignancies seen in animal studies, a pediatric subcommittee of the FDA's Anti-Infective Drugs Advisory Committee said topical immunosuppressant labeling should include a warning against use in children under the age of two.
Beware Drug Resistance, Interactions
December 1st 2003Las Vegas -- Dermatologists must avoid the shotgun approach to antibiotics and pay more attention to potential drug interactions, said James Q. Del Rosso, D.O., F.A.O.C.D. This way, they can avoid contributing to two alarming trends in pharmacologic therapy: antibiotic resistance and potentially significant dangerous drug reactions.